Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 15, 2015 - Issue 11
Submit an article Journal homepage
386
Views
4
CrossRef citations to date
0
Altmetric
Reviews

Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children

Giovanna VitalitiGeneral Paediatrics Operative Unit, Policlinico-Vittorio-Emanuele University Hospital, University of Catania, Catania, ItalyCorrespondence[email protected]
,
Nassim MatinTehran University of Medical Sciences, Tehran, Iran
,
Omidreza TabatabaieTehran University of Medical Sciences, Tehran, Iran
,
Mario Di TragliaDepartment of Statistics, La Sapienza University of Rome, Rome, Italy
,
Piero PavoneGeneral Paediatrics Operative Unit, Policlinico-Vittorio-Emanuele University Hospital, University of Catania, Catania, Italy
,
Riccardo LubranoPaediatric Department, Paediatric Nephrology Operative Unit, Sapienza University of Rome, Rome, Italy
&
Raffaele FalsaperlaGeneral Paediatrics Operative Unit, Policlinico-Vittorio-Emanuele University Hospital, University of Catania, Catania, Italy
 show all
Pages 1321-1341 | Published online: 29 Oct 2015

References

  • Papers of special note have been highlighted as:
  • * of interest to readers
  • ** of considerable interest to readers
  • Høglund RA, Maghazachi AA. Multiple sclerosis and the role of immune cells. World J Exp Med. 2014;4(3):27. DOI:10.5493/wjem.v4.i3.27. eCollection 2014.
  • Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int. 2014;2014. DOI:10.1155/2014/262350.
  • Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin. Nature. 1992;356(6364):63–66.
  • Stefanich E, Danilenko D, Wang H, et al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011;162(8):1855–1870. DOI:10.1111/j.1476-5381.2011.01205.x.
  • Steinman L. The discovery of natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol. 2012;199(3):413–416. DOI:10.1083/jcb.201207175.
  • Filippi M, Rocca MA, Bastianello S, et al. Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurol Sci. 2013;34(12):2085–2093. DOI:10.1007/s10072-013-1485-7.
  • Lublin F. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J Neurol. 2005;252(5):v46–v53.
  • Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. Brain. 1989;112(1):133–146.
  • Kurtzke JF. Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology. 2008;31(1):1–9. DOI:10.1159/000136645.
  • Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85(11):1190–1197. DOI:10.1136/jnnp-2013-306936.

**Together with the STRATA study, this is one of the large observational studies on efficacy and safety of NTZ in MS patients

  • O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83(1):78–86. DOI:10.1212/WNL.0000000000000541.

**Another important study on efficiency and safety of NTZ in MS

  • Oturai AB, Koch‐Henriksen N, Petersen T, et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009;16(3):420–423. DOI:10.1111/j.1468-1331.2008.02517.x.
  • Outteryck O, Ongagna J-C, Zéphir H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010;257(2):207–211. DOI:10.1007/s00415-009-5294-0.
  • Piehl F, Holmén C, Hillert J, et al. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci. 2011;31(3):289–293. DOI:10.1007/s10072-010-0345-y.
  • Prosperini L, Borriello G, Fubelli F, et al. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci. 2011;31(3):303–307. DOI:10.1007/s10072-010-0348-8.

* An interesting paper on the Italian experience of NTZ on MS patients

  • Fernández O, Alvarenga MP, Guerrero M, et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler J. 2011;17(2):192–197. DOI:10.1177/1352458510385507.
  • Fernandez-Megia M, Casanova B, Magraner M, et al. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis. Farm Hosp (English Edition). 2011;35(2):75–79. DOI:10.1016/j.farma.2010.02.003.
  • Sangalli F, Moiola L, Bucello S, et al. Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. 2011;31(3):299–302. DOI:10.1007/s10072-010-0344-z.
  • Kallweit U, Jelcic I, Braun N, et al. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol. 2012;35(2):77–80. DOI:10.1097/WNF.0b013e31824644e6.
  • Melin A, Outteryck O, Collongues N, et al. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol. 2012;259(6):1215–1221. DOI:10.1007/s00415-011-6339-8.
  • Popova E, Brylev L, Davydovskaya M. Preliminary results of the “sovet” observational program for use of natalizumab in the treatment of patients with remitting multiple sclerosis. Neurosci Behav Physiol. 2014;44(5):520–523.
  • Van Pesch V, Bartholomé E, Bissay V, et al. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. Acta Neurol Belg. 2014;114(3):167–178. DOI:10.1007/s13760-014-0308-9.
  • Putzki N, Yaldizli Ö, Bühler R, et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol. 2010;63(2):101–106. DOI:10.1159/000276400.
  • Putzki N, Yaldizli O, Mäurer M, et al. Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countries. Eur J Neurol. 2010;17(1):31–37. DOI:10.1111/j.1468-1331.2009.02728.x.
  • Holmén C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler J. 2011;17(6):708–719. DOI:10.1177/1352458510394701.
  • Fernández O, Oreja-Guevara C, Arroyo R, et al. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol. 2012;259(9):1814–1823.
  • Sousa L, Sá J, Sá M, et al. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study. Rev Neurol. 2014;59(9):399–406.
  • Outteryck O, Ongagna J, Brochet B, et al. A prospective observational post‐marketing study of natalizumab‐treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol. 2014;21(1):40–48. DOI:10.1111/ene.12204.
  • Tubridy N, Behan P, Capildeo R, et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology. 1999;53(3):466–472.
  • Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med. 2003;348(1):15–23.
  • Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol. 2004;251(4):407–413.
  • O’connor P, Goodman A, Willmer-Hulme A, et al. Randomized multicenter trial of natalizumab in acute MS relapses Clinical and MRI effects. Neurology. 2004;62(11):2038–2043.
  • Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med. 2006;354(9):899–910.

** A well-known RCT on NTZ, reporting a wide number of side adverse events of NTZ on MS patients, useful to evaluate the safety aspect of this therapy

  • Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med. 2006;354(9):911–923.
  • Goodman A, Rossman H, Bar-Or A, et al. GLANCE results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806–812. DOI:10.1212/01.wnl.0000343880.13764.69.
  • Kappos L, O’Connor PW, Polman CH, et al. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol. 2013;260(5):1388–1395. DOI:10.1007/s00415-012-6809-7.
  • Miller D, Soon D, Fernando K, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68(17):1390–1401.
  • Calabresi P, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391–1403.
  • Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256(3):405–415. DOI:10.1007/s00415-009-0093-1.
  • Radue E-W, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci. 2010;292(1):28–35. DOI:10.1016/j.jns.2010.02.012.
  • Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler J. 2011;17(8):970–979. DOI:10.1177/1352458511399611.
  • Cree BA, Stuart WH, Tornatore CS, et al. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011;68(4):464–468. DOI:10.1001/archneurol.2011.45.
  • Weinstock-Guttman B, Galetta SL, Giovannoni G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol. 2012;259(5):898–905. DOI:10.1007/s00415-011-6275-7.
  • Bates D, Bartholomé E. Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity. J Neurol Neurosurg Psychiatry. 2012;83(1):55–60. DOI:10.1136/jnnp-2011-300279.
  • Cohen J, Cutter G, Fischer J, et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59(5):679–687.
  • Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013;8(1):e53297. DOI:10.1371/journal.pone.0053297.
  • Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. New Engl J Med. 2005;353(4):375–381.
  • Kleinschmidt-DeMasters B, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. New Engl J Med. 2005;353(4):369–374.
  • Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. New Engl J Med. 2005;353(4):362–368.
  • Chaudhuri A. Drugs: lessons for clinical trials from natalizumab in multiple sclerosis. BMJ. 2006;332(7538):416.
  • Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl J Med. 2006;354(9):924–933.
  • Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–446. DOI:10.1016/S1474-4422(10)70028-4.
  • Mancardi G, Tedeschi G, Amato M, et al. Three years of experience: the Italian registry and safety data update. Neurol Sci. 2011;31(3):295–297. DOI:10.1007/s10072-010-0356-8.
  • Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New Engl J Med. 2012;366(20):1870–1880. DOI:10.1056/NEJMoa1107829.
  • Dentistry BaTLSoMa. June 2014 natalizumab PML update: are we underestimating the PML risk? July 2014.
  • Dentistry BaTLSoMa. December 2014 natalizumab PML update: underestimating the PML risk? Dec 2014.
  • Tan CS, Koralnik IJ. Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system. Lancet Neurol. 2010;9(4):425. DOI:10.1016/S1474-4422(10)70040-5.
  • Engsig FN, Hansen A-BE, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77–83.
  • Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63(10):1383–1387.
  • Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. New Engl J Med. 2009;361(11):1067–1074. DOI:10.1056/NEJMoa0904267.
  • Carruthers RL, Berger J. Progressive multifocal leukoencephalopathy and JC virus-related disease in modern neurology practice. Mult Scler Relat Disord. 2014;3(4):419–430. DOI:10.1016/j.msard.2014.01.00.
  • Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76(20):1697–1704. DOI:10.1212/WNL.0b013e31821a446b.
  • Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. 2013;84:1068–1074 ( jnnp-2013-304897).
  • Outteryck O, Ongagna J-C, Duhamel A, et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol. 2012;259(11):2293–2298. DOI:10.1007/s00415-012-6487-5.
  • da Silva AM, Santos ME, Investigators PJS. JCV epidemiology in MS (JEMS)—epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients—Portuguese data. J Neurol Sci. 2014;337(1):119–122. DOI:10.1016/j.jns.2013.11.031.
  • Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57(2):141–146. DOI:10.1016/j.jcv.2013.02.002.
  • Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler J. 2013;19(11):1533–1538. DOI:10.1177/1352458513477925.
  • Bozic C, Subramanyam M, Richman S, et al. Anti‐JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol. 2014;21(2):299–304. DOI:10.1111/ene.12304.
  • Plavina T, Subramanyam M, Bloomgren G, et al. Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802–812. DOI:10.1002/ana.24286.
  • Tur C, Montalban X. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs. 2014;28(7):641–648. DOI:10.1007/s40263-014-0168-0.
  • Cutter GR, Stüve O. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler J. 2014;20(10):1304–1305. DOI:10.1177/1352458514531843.
  • Durali D, de Goër de Herve M-G, Gasnault J, et al. B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol. 2015;6:241. DOI:10.3389/fimmu.2015.00241.
  • Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol. 2001;75(7):3483–3487.
  • Gasnault J, Kahraman M, De Herve M, et al. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. Aids. 2013;17(10):1443–1449.
  • Grewal IS, Foellmer HG, Grewal KD, et al. CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis. Immunity. 2001;14(3):291–302.
  • Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81(10):865–871. DOI:10.1212/WNL.0b013e3182a351fb.
  • Jilek S, Mathias A, Canales M, et al. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients. Mult Scler. Epub 2013 Nov 20.
  • Muñoz-Culla M, Irizar H, Castillo-Triviño T, et al. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler J. 2014;20(14):1851–1859. DOI:10.1177/1352458514534513.
  • Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection Clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458–1464. DOI:10.1212/01.wnl.0000343510.08643.74.
  • Berger JR. Steroids for PML-IRIS A double-edged sword? Neurology. 2009;72(17):1454–1455. DOI:10.1212/01.wnl.0000343735.44983.5e.
  • Diotti RA, Nakanishi A, Clementi N, et al. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? Clin Dev Immunol. 2013;2013:967581. DOI:10.1155/2013/967581.
  • Vellinga M, Castelijns J, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70(13 Part 2):1150–1151.
  • Stüve O, Cravens P, Frohman E, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72(5):396–401. DOI:10.1212/01.wnl.0000327341.89587.76.
  • Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68(3):392–395. DOI:10.1002/ana.22074.
  • O’Connor P, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858–1865. DOI:10.1212/WNL.0b013e31821e7c8a.
  • Schaaf SM, Pitt D, Racke MK. What happens when natalizumab therapy is stopped? Expert Rev Neurother. 2011;11(9):1247–1250. DOI:10.1586/ern.11.109.
  • Borriello G, Prosperini L, Marinelli F, et al. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler J. 2011;17(3):372–375. DOI:10.1177/1352458510392098.
  • Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol. 2011;258(9):1665–1669. DOI:10.1007/s00415-011-5996-y.
  • Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci. 2011;308(1):98–102. DOI:10.1016/j.jns.2011.05.043.
  • Magraner MJ, Coret F, Navarré A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol. 2011;258(10):1805–1811. DOI:10.1007/s00415-011-6019-8.
  • Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post‐marketing study. Eur J Neurol. 2012;19(5):783–787. DOI:10.1111/j.1468-1331.2011.03577.x.
  • Grimaldi LM, Prosperini L, Vitello G, et al. MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis. Mult Scler J. 2012;18(9):1337–1339. DOI:10.1177/1352458512439438.
  • Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol. 2013;20(1):87–94. DOI:10.1111/j.1468-1331.2012.03794.x.
  • Melis M, Cocco E, Frau J, et al. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurol Sci. 2014;35(3):401–408. DOI:10.1007/s10072-013-1527-1.
  • Clerico M, Schiavetti I, De Mercanti SF, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol. 2014;71(8):954–960. DOI:10.1001/jamaneurol.2014.
  • Vidal-Jordana A, Tintoré M, Tur C, et al. Significant clinical worsening after natalizumab withdrawal: predictive factors. Mult Scler J. 2015;21(6):780–785. DOI:10.1177/1352458514549401.
  • Ferrè L, Moiola L, Sangalli F, et al. Recurrence of disease activity after repeated Natalizumab withdrawals. Neurol Sci. 2015;36(3):465–467. DOI:10.1007/s10072-014-1960-9.
  • Gobbi C, Meier DS, Cotton F, et al. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol. 2013;13(1):101. DOI:10.1186/1471-2377-13-101.
  • Fox RJ, Cree BA, De Sèze J, et al. MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491–1498. DOI:10.1212/WNL.0000000000000355.
  • Kaufman M, Cree BA, De Sèze J, et al. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol. 2015;262(2):326–336. DOI:10.1007/s00415-014-7558-6.
  • Waldman A, Ghezzi A, Bar-Or A, et al. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol. 2014;13(9):936–948. DOI:10.1016/S1474-4422(14)70093-6.
  • Yeh EA, Chitnis T, Krupp L, et al. Pediatric multiple sclerosis. Nat Rev Neurol. 2009;5(11):621–631. DOI:10.1038/nrneurol.2009.158.
  • Gorman MP, Healy BC, Polgar-Turcsanyi M, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54–59. DOI:10.1001/archneurol.2008.505.
  • Narula S, Hopkins SE, Banwell B. Treatment of pediatric multiple sclerosis. Curr Treat Options Neurol. 2015;17(3):1–12. DOI:10.1007/s11940-014-0336-z.
  • Yeh EA, Waubant E, Krupp LB, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol. 2011;68(4):437–444. DOI:10.1001/archneurol.2010.325.
  • Huppke P, Stark W, Zürcher C, et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008;65(12):1655–1658. DOI:10.1001/archneur.65.12.1655.

* This is an interesting paper on the use of Natalizumab in pediatric patient affected by MS

  • Borriello G, Prosperini L, Luchetti A, et al. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatric Neurol. 2009;13(1):67–71. DOI:10.1016/j.ejpn.2008.01.007.
  • Putzki N, Stich O, Gartzen K, et al. Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de‐escalation and escalation. Eur J Neurol. 2010;17(11):e105. DOI:10.1111/j.1468-1331.2010.03178.x.
  • Ghezzi A, Pozzilli C, Grimaldi L, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75(10):912–917. DOI:10.1212/WNL.0b013e3181f11daf.
  • Arnal-Garcia C, García-Montero MR, Málaga I, et al. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatric Neurol. 2013;17(1):50–54. DOI:10.1016/j.ejpn.2012.09.004.
  • Ghezzi A, Pozzilli C, Grimaldi L, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler J. 2013;19(8):1106–1112. DOI:10.1177/1352458512471878.
  • Kornek B, Aboul-Enein F, Rostasy K, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013;70(4):469–475. DOI:10.1001/jamaneurol.2013.923.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.